JP2026026092A5 - - Google Patents

Info

Publication number
JP2026026092A5
JP2026026092A5 JP2025184688A JP2025184688A JP2026026092A5 JP 2026026092 A5 JP2026026092 A5 JP 2026026092A5 JP 2025184688 A JP2025184688 A JP 2025184688A JP 2025184688 A JP2025184688 A JP 2025184688A JP 2026026092 A5 JP2026026092 A5 JP 2026026092A5
Authority
JP
Japan
Prior art keywords
cov
fraction
glycoprotein
quillaja saponaria
saponaria molina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025184688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026026092A (ja
Filing date
Publication date
Priority claimed from US16/997,001 external-priority patent/US10953089B1/en
Priority claimed from JP2022545141A external-priority patent/JP7792339B2/ja
Application filed filed Critical
Publication of JP2026026092A publication Critical patent/JP2026026092A/ja
Publication of JP2026026092A5 publication Critical patent/JP2026026092A5/ja
Pending legal-status Critical Current

Links

JP2025184688A 2020-01-27 2025-10-31 コロナウイルスワクチン製剤 Pending JP2026026092A (ja)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US202062966271P 2020-01-27 2020-01-27
US62/966,271 2020-01-27
US202062976858P 2020-02-14 2020-02-14
US62/976,858 2020-02-14
US202062983180P 2020-02-28 2020-02-28
US62/983,180 2020-02-28
US202063048945P 2020-07-07 2020-07-07
US63/048,945 2020-07-07
US202063051706P 2020-07-14 2020-07-14
US63/051,706 2020-07-14
US202063054182P 2020-07-20 2020-07-20
US63/054,182 2020-07-20
US16/997,001 2020-08-19
US16/997,001 US10953089B1 (en) 2020-01-27 2020-08-19 Coronavirus vaccine formulations
US202063129392P 2020-12-22 2020-12-22
US63/129,392 2020-12-22
JP2022545141A JP7792339B2 (ja) 2020-01-27 2021-01-27 コロナウイルスワクチン製剤
PCT/US2021/015220 WO2021154812A1 (en) 2020-01-27 2021-01-27 Coronavirus vaccine formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022545141A Division JP7792339B2 (ja) 2020-01-27 2021-01-27 コロナウイルスワクチン製剤

Publications (2)

Publication Number Publication Date
JP2026026092A JP2026026092A (ja) 2026-02-16
JP2026026092A5 true JP2026026092A5 (https=) 2026-03-10

Family

ID=77079351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022545141A Active JP7792339B2 (ja) 2020-01-27 2021-01-27 コロナウイルスワクチン製剤
JP2025184688A Pending JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022545141A Active JP7792339B2 (ja) 2020-01-27 2021-01-27 コロナウイルスワクチン製剤

Country Status (14)

Country Link
US (1) US20230070886A1 (https=)
EP (1) EP4097123A4 (https=)
JP (2) JP7792339B2 (https=)
KR (1) KR20220141302A (https=)
CN (1) CN115720581A (https=)
AU (1) AU2021214064A1 (https=)
BR (1) BR112022014830A2 (https=)
CA (1) CA3165371A1 (https=)
GB (1) GB2610070A (https=)
IL (1) IL295142A (https=)
MX (1) MX2022009167A (https=)
TW (1) TW202142555A (https=)
WO (1) WO2021154812A1 (https=)
ZA (1) ZA202401922B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
WO2022235663A1 (en) * 2021-05-05 2022-11-10 Novavax, Inc. Coronavirus and influenza compositions and methods for using them
CN113773372B (zh) * 2021-08-15 2024-08-02 北京科兴中维生物技术有限公司 重组蛋白及其制备方法和应用
CN116041448B (zh) * 2021-08-26 2025-05-13 江苏瑞科生物技术股份有限公司 新型冠状病毒免疫原性物质、其制备方法和应用
EP4436984A1 (en) * 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Coronavirus immunogen compositions and their uses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
KR20240125935A (ko) * 2021-11-30 2024-08-20 노바백스, 인코포레이티드 코로나바이러스 백신 제형물
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
EP4709741A1 (en) * 2023-05-12 2026-03-18 Icosavax, Inc. Coronavirus spike glycoprotein receptor binding domains and uses thereof
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1508615A1 (en) * 2003-08-18 2005-02-23 Amsterdam Institute of Viral Genomics B.V. Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
US20070124833A1 (en) * 2005-05-10 2007-05-31 Abad Mark S Genes and uses for plant improvement
JP5813513B2 (ja) * 2008-12-09 2015-11-17 ノババックス,インコーポレイテッド 修飾rsvfタンパク質及びその使用方法
US20130122032A1 (en) * 2011-09-30 2013-05-16 Gale Smith Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
KR102399854B1 (ko) * 2013-09-19 2022-05-19 노바백스, 인코포레이티드 면역원성 중동호흡기증후군 코로나바이러스 (ΜERS-CoV) 조성물 및 방법
EP4494650A3 (en) * 2015-09-03 2025-03-26 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
US20170354729A1 (en) * 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
EP4599847A3 (en) * 2016-10-25 2025-11-12 Trustees of Dartmouth College Prefusion coronavirus spike proteins and their use
MA47790A (fr) * 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
CN111499692B (zh) * 2020-06-16 2020-12-04 国家纳米科学中心 靶向新型冠状病毒covid-19的多肽及其应用

Similar Documents

Publication Publication Date Title
JP2026026092A5 (https=)
AU765824B2 (en) Vaccines
AU766635B2 (en) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
Almeida et al. Nasal delivery of vaccines
JP2019526580A5 (https=)
US20150064216A1 (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
US20040047882A1 (en) Adjuvant for vaccines
JPWO2021154812A5 (https=)
CN112439058A (zh) 基于外泌体为载体的重组新型冠状病毒纳米疫苗方法
JP7618632B2 (ja) 経鼻b型肝炎ワクチン組成物およびその製造方法
JPWO2022203963A5 (https=)
US20240261392A1 (en) Compositions and methods to increase coronavirus immune response
WO1998046263A1 (en) Saponin adjuvants in combination with dna vaccination
EP1987840B1 (en) Prime-boost vaccine for the protection of equines against viral infection
JPWO2023102448A5 (https=)
WO2023159082A2 (en) Nanotechnology based intranasal vaccine for covid-19 comprising chitosan
Udaya Kumar et al. Nasal vaccine as a booster shot: a viable solution to restrict pandemic?
AU2023347247A1 (en) Methods and materials for using adenovirus vectors to immunize mammals
WO2023159081A2 (en) Nanotechnology based intranasal vaccine for covid-19
RU2023126867A (ru) Вакцинные составы против коронавируса
Verges World Vaccine Congress Europe 2017. Barcelona, Spain-October 10-12, 2017
ZA200202268B (en) Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one non-ionic surfactant.
JPWO2023102375A5 (https=)
AU2013206335A1 (en) dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
JPWO2022155476A5 (https=)